# Investigating the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences

**Authors:** Bill Deakin, Elizabeth Liddle, Mohanbabu Rathnaiah, Catherine C. Gregory, Mohammad Z. Katshu, Gemma Williams, Silke Conen, Richard Smallman, Loes C. Koelewijn, Adriana Anton, Jyothika Kumar, Lauren E. Gascoyne, Chen Chen, Naghmeh Nikkheslat, John Evans, Bernard Lanz, James Walters, Peter S. Talbot, Lena Palaniyappan, Krish D. Singh, Peter Morris, Stephen R. Williams, Peter F. Liddle

PMC · DOI: 10.1038/s41380-025-03337-x · 2025-11-19

## TL;DR

This study explores how changes in brain chemicals like glutamate and GABA may contribute to psychosis in schizophrenia, finding that GABA levels are lower in patients and linked to symptom severity.

## Contribution

The study provides new evidence that GABA reduction in the dACC is associated with symptom severity in schizophrenia, independent of inflammation or oxidative stress.

## Key findings

- Established schizophrenia patients show a greater glutamate deficit in the dACC compared to recently diagnosed patients.
- GABA levels in the dACC correlate with symptom severity across both recent and established schizophrenia groups.
- Glutamate deficits in established illness are not explained by inflammation, oxidative stress, or antipsychotic exposure.

## Abstract

We investigated the longstanding idea that the onset of psychotic symptoms in schizophrenia arises from an early phase of glutamate neurotoxicity, possibly related to loss of GABA restraint, oxidative stress or inflammation, that cumulatively results in a later phase of synaptic loss in keeping with magnetic resonance spectroscopy (MRS) evidence of reduced glutamate in schizophrenia, especially in older patients. We evaluated this hypothesis in a 3-centre MRS study to determine whether abnormalities in glutamate in dorsal anterior cingulate cortex (dACC) differed between people with minimally treated ‘Recent’ onset schizophrenia and an ‘Established’ group with > 10 years of illness. We tested the hypothesised mechanisms of reduced GABA in either or both dACC and occipital cortex, and depletion of dACC glutathione, a measure of central inflammation. We explored predicted associations between MRS variables, circulating cytokines and clinical symptoms. The Established group showed significantly greater dACC glutamate deficit than the Recent group which was not accounted for by lifetime exposure to antipsychotic drugs or by their greater CRP or IL-6 levels nor was the deficit associated with glutathione depletion. The greater dACC glutamate deficit in established illness is compatible with loss of synapses occurring after onset of symptoms but there was little to suggest underpinning excitotoxicity, inflammation, or oxidative stress. GABA was reduced in patients versus controls across dACC and occipital voxels. Only dACC GABA content correlated significantly with symptoms, lower content with greater positive and negative symptoms across both groups and this is supportive of a pathophysiological role of GABA in psychosis.

## Linked entities

- **Chemicals:** glutamate (PubChem CID 611), GABA (PubChem CID 119), glutathione (PubChem CID 124886), IL-6 (PubChem CID 165368475)
- **Diseases:** schizophrenia (MONDO:0005090), psychosis (MONDO:0005485)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** neurotoxicity (MESH:D020258), inflammation (MESH:D007249), psychosis (MESH:D011618), schizophrenia (MESH:D012559)
- **Chemicals:** GABA (MESH:D005680), glutathione (MESH:D005978), glutamate (MESH:D018698)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12999488/full.md

---
Source: https://tomesphere.com/paper/PMC12999488